Affimed (AFMD) Misses Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Affimed (AFMD) Misses Q1 EPS by 8c

Affimed Reports Financial Results for First Quarter 2016

May 18, 2016 7:30 AM EDT

HEIDELBERG, Germany, May 18, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported financial results for the quarter ended March 31, 2016.

"IO combination therapies, like our lead drug AFM13 in combination with our partner Merck's Keytruda, may offer a similarly high efficacy with significantly less toxicity compared to current frontline treatments of Hodgkin lymphoma patients. According to the KOLs, this would represent a significant advancement over chemotherapy, which causes life-long debilitating side effects," said Dr. Adi Hoess, CEO of... More